Common Side Effects and Their Frequency
Icosapent ethyl (Vascepa), used to lower triglycerides, has side effects in clinical trials that are mostly mild. In the pivotal REDUCE-IT trial, 11% of patients on icosapent discontinued due to adverse events, compared to 9% on placebo.[1] The most frequent include:
- Joint pain (arthralgia): 2.3% vs. 2.1% placebo.
- Gout: 1.7% vs. 1.1%.
- Muscle pain (myalgia): 1.6% vs. 1.5%.
- Atrial fibrillation: 5.3% vs. 3.9%.
- Bleeding (e.g., epistaxis): 2.5% vs. 2.1%.[2]
These rates show small increases over placebo, suggesting many are not directly caused by the drug.
Serious Side Effects and Rare Risks
Serious risks occur infrequently:
- Hemorrhagic stroke: 0.3% vs. 0.1% placebo.
- Gastrointestinal bleeding: 0.7% vs. 0.3%.[2]
Hypertriglyceridemia patients have baseline cardiovascular risks, so these events may reflect the population rather than the drug alone. No increased cancer risk was observed.[1]
Factors Raising Side Effect Likelihood
- Dose: 4g/day doubles some risks vs. lower doses in trials.
- Comorbidities: Diabetes (common in users) links to higher gout and bleeding rates.
- Anticoagulants: Combining with blood thinners elevates bleeding risk by 1.5-2x per FDA label.[3]
- Duration: Effects stable over 5 years in REDUCE-IT; no cumulative worsening.
Elderly patients (>65) report 10-15% higher arthralgia incidence.[2]
How Patients Report Experiencing Them
Real-world data from FDA adverse event reports (FAERS) show over 10,000 icosapent-related submissions since approval, with muscle/joint issues (25%), bleeding (15%), and rash (10%) topping lists. Underreporting is common; trial rates better predict population likelihood.[4] Patient forums note 20-30% mention mild GI upset not highlighted in trials.
Comparison to Placebo and Alternatives
Placebo-adjusted rates are low (e.g., <2% excess for most), indicating good tolerability. Vs. fenofibrate (another TG-lowering drug), icosapent has 40% fewer discontinuations.[5] Statin combos show no amplified myopathy risk.
[1]: REDUCE-IT Trial (NEJM, 2019)
[2]: Vascepa Prescribing Information (FDA)
[3]: FDA Label Warnings
[4]: FAERS Database (FDA)
[5]: ANCHOR Trial Meta-Analysis